Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more
Market Cap & Net Worth: Aytu BioScience Inc (AYTU)
Aytu BioScience Inc (NASDAQ:AYTU) has a market capitalization of $27.91 Million ($27.91 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25534 globally and #8706 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aytu BioScience Inc's stock price $2.60 by its total outstanding shares 10733208 (10.73 Million).
Aytu BioScience Inc Market Cap History: 2015 to 2026
Aytu BioScience Inc's market capitalization history from 2015 to 2026. Data shows change from $10.73 Trillion to $27.91 Million (-70.99% CAGR).
Index Memberships
Aytu BioScience Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #678 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #2197 of 3165 |
Weight: Aytu BioScience Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aytu BioScience Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aytu BioScience Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Aytu BioScience Inc's market cap is 0.42 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.03 Trillion | $2.56 Million | -$28.18 Million | 402111.25x | N/A |
| 2017 | $95.74 Billion | $3.22 Million | -$22.51 Million | 29718.31x | N/A |
| 2018 | $1.70 Billion | $3.66 Million | -$10.19 Million | 464.75x | N/A |
| 2019 | $2.09 Billion | $7.32 Million | -$47.17 Million | 285.18x | N/A |
| 2020 | $1.28 Billion | $27.63 Million | -$13.62 Million | 46.46x | N/A |
| 2021 | $289.80 Million | $65.63 Million | -$58.29 Million | 4.42x | N/A |
| 2022 | $40.57 Million | $96.67 Million | -$108.78 Million | 0.42x | N/A |
| 2023 | $30.48 Million | $107.40 Million | -$17.05 Million | 0.28x | N/A |
| 2024 | $18.25 Million | $65.18 Million | -$15.84 Million | 0.28x | N/A |
| 2025 | $27.91 Million | $66.38 Million | -$13.56 Million | 0.42x | N/A |
Competitor Companies of AYTU by Market Capitalization
Companies near Aytu BioScience Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Aytu BioScience Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Aytu BioScience Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Aytu BioScience Inc's market cap moved from $10.73 Trillion to $ 27.91 Million, with a yearly change of -70.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $27.91 Million | 0.00% |
| 2025 | $27.91 Million | +52.94% |
| 2024 | $18.25 Million | -40.14% |
| 2023 | $30.48 Million | -24.87% |
| 2022 | $40.57 Million | -86.00% |
| 2021 | $289.80 Million | -77.42% |
| 2020 | $1.28 Billion | -38.51% |
| 2019 | $2.09 Billion | +22.73% |
| 2018 | $1.70 Billion | -98.22% |
| 2017 | $95.74 Billion | -90.71% |
| 2016 | $1.03 Trillion | -90.40% |
| 2015 | $10.73 Trillion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Aytu BioScience Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $27.91 Million USD |
| MoneyControl | $27.91 Million USD |
| MarketWatch | $27.91 Million USD |
| marketcap.company | $27.91 Million USD |
| Reuters | $27.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.